REGENXBIO (NASDAQ:RGNX – Get Free Report) is projected to issue its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect REGENXBIO to announce earnings of $0.12 per share and revenue of $97.6290 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Thursday, August 6, 2026 at 8:00 AM ET.
REGENXBIO (NASDAQ:RGNX – Get Free Report) last issued its quarterly earnings data on Thursday, May 14th. The biotechnology company reported ($1.72) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.36) by ($0.36). REGENXBIO had a negative return on equity of 232.50% and a negative net margin of 330.23%.The firm had revenue of $6.39 million for the quarter, compared to the consensus estimate of $25.84 million. On average, analysts expect REGENXBIO to post $-4 EPS for the current fiscal year and $-3 EPS for the next fiscal year.
REGENXBIO Trading Up 0.2%
REGENXBIO stock opened at $9.62 on Thursday. REGENXBIO has a 12 month low of $5.45 and a 12 month high of $16.19. The stock’s 50 day moving average is $9.49 and its 200-day moving average is $9.59. The company has a market capitalization of $497.35 million, a price-to-earnings ratio of -1.72 and a beta of 0.90.
Insider Buying and Selling at REGENXBIO
Hedge Funds Weigh In On REGENXBIO
A number of hedge funds have recently added to or reduced their stakes in the stock. State Street Corp raised its holdings in REGENXBIO by 15.2% in the 4th quarter. State Street Corp now owns 2,286,736 shares of the biotechnology company’s stock valued at $32,929,000 after acquiring an additional 301,858 shares in the last quarter. AQR Capital Management LLC grew its holdings in shares of REGENXBIO by 5.6% during the 4th quarter. AQR Capital Management LLC now owns 1,361,962 shares of the biotechnology company’s stock worth $19,612,000 after purchasing an additional 72,307 shares in the last quarter. Integral Health Asset Management LLC increased its position in shares of REGENXBIO by 9.1% in the fourth quarter. Integral Health Asset Management LLC now owns 1,200,000 shares of the biotechnology company’s stock worth $17,280,000 after purchasing an additional 100,000 shares during the period. Geode Capital Management LLC increased its position in shares of REGENXBIO by 1.7% in the fourth quarter. Geode Capital Management LLC now owns 1,145,206 shares of the biotechnology company’s stock worth $16,495,000 after purchasing an additional 19,658 shares during the period. Finally, Nuveen LLC increased its position in shares of REGENXBIO by 19.3% in the fourth quarter. Nuveen LLC now owns 658,510 shares of the biotechnology company’s stock worth $9,483,000 after purchasing an additional 106,363 shares during the period. Institutional investors own 88.08% of the company’s stock.
Analysts Set New Price Targets
Several research firms recently weighed in on RGNX. Leerink Partners lifted their price target on REGENXBIO from $17.00 to $18.00 and gave the stock an “outperform” rating in a report on Monday, June 22nd. Zacks Research lowered REGENXBIO from a “hold” rating to a “strong sell” rating in a report on Tuesday, July 14th. Weiss Ratings reiterated a “sell (e+)” rating on shares of REGENXBIO in a research report on Monday, June 8th. Robert W. Baird lifted their target price on REGENXBIO from $27.00 to $32.00 and gave the stock an “outperform” rating in a report on Monday, June 22nd. Finally, Barclays reduced their target price on shares of REGENXBIO from $37.00 to $12.00 and set an “overweight” rating for the company in a research report on Friday, May 15th. Ten equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $23.82.
View Our Latest Research Report on RGNX
About REGENXBIO
REGENXBIO Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies using its proprietary NAV® AAV (adeno‐associated virus) platform. The company engineers next‐generation AAV vectors designed to deliver functional genes to targeted cells, aiming to address a range of rare genetic diseases and ocular, metabolic and neurologic disorders. REGENXBIO’s pipeline features several product candidates in various stages of preclinical and clinical development, including RGX-314 for wet age‐related macular degeneration, RGX-121 for mucopolysaccharidosis II (Hunter syndrome) and RGX-121 for other rare lysosomal storage diseases.
In addition to its internally funded programs, REGENXBIO has established partnerships with major biopharmaceutical companies to advance its NAV technology.
Read More
- Five stocks we like better than REGENXBIO
- Why SK hynix Could Be the Best AI Chip Stock to Buy Now
- Seagate Technology Stock Surges as Earnings Beat Silences AI Doubters
- Alphabet Is Down 18% From Its High After a Stellar Quarter—Overdone, or More Downside Ahead?
- Why Bloom Energy May Be the Most Important AI Infrastructure Stock
Receive News & Ratings for REGENXBIO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REGENXBIO and related companies with MarketBeat.com's FREE daily email newsletter.
